• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

环氧酮与硼化肽在玻碳电极和硼掺杂金刚石电极上的电荷转移反应机理

Charge transfer reaction mechanisms of epoxyketone and boronated peptides at glassy carbon and boron doped diamond electrodes.

作者信息

de Jesus Catarina Sofia Henriques, Enache Teodor Adrian, Diculescu Victor Constantin

机构信息

Laboratory of Electroanalysis and Corrosion, Instituto Pedro Nunes, Coimbra, Portugal.

National Institute of Material Physics, Atomistilor 405A, 077125 Magurele, Romania.

出版信息

J Electroanal Chem (Lausanne). 2020 Dec 1;878:114733. doi: 10.1016/j.jelechem.2020.114733. Epub 2020 Sep 30.

DOI:10.1016/j.jelechem.2020.114733
PMID:33020701
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7526604/
Abstract

The ubiquitin-proteasome system regulates the level of proteins within cells through controlled proteolysis. In some diseases, the system function is dysregulated turning the ubiquitin-proteasome complex into a target for drug development. The redox behavior of proteasome inhibitors, epoxyketone and boronated peptides carfilzomib, oprozomib and delanzomib was investigated by voltammetric methods using glassy carbon and boron doped diamond electrodes. It was showed that the oxidation of epoxyketone peptides carfilzomib and oprozomib occurred in one step at glassy carbon electrode surface while at boron doped diamond two consecutive charge transfer reactions due to different adsorption orientation at the electrode surface were observed. The moieties of these peptides, involved in the oxidation process, were morpholine for carfilzomib and thiazole for oprozomib. For the boronated peptide delanzomib, two irreversible and independent redox processes, oxidation at +0.80 V and reduction at -1.40 V were identified in neutral media at both electrodes. The oxidation reaction occurred at the amino group close to the pyridine moiety of delanzomib with the transfer of one electron and one proton whereas the reduction process takes place at pyridine ring in a two-electrons two-protons mechanism. Redox mechanisms were proposed and the implications on the proteasome inhibition discussed.

摘要

泛素 - 蛋白酶体系统通过可控的蛋白水解作用调节细胞内蛋白质的水平。在某些疾病中,该系统功能失调,使得泛素 - 蛋白酶体复合物成为药物开发的靶点。使用玻碳电极和硼掺杂金刚石电极,通过伏安法研究了蛋白酶体抑制剂环氧酮和硼化肽卡非佐米、奥布佐米和德兰佐米的氧化还原行为。结果表明,环氧酮肽卡非佐米和奥布佐米在玻碳电极表面一步发生氧化,而在硼掺杂金刚石电极上,由于电极表面不同的吸附取向,观察到两个连续的电荷转移反应。这些肽参与氧化过程的部分,卡非佐米是吗啉环,奥布佐米是噻唑环。对于硼化肽德兰佐米,在两个电极的中性介质中都鉴定出两个不可逆且独立的氧化还原过程,在 +0.80 V 处氧化,在 -1.40 V 处还原。氧化反应发生在靠近德兰佐米吡啶部分的氨基上,转移一个电子和一个质子,而还原过程以双电子双质子机制在吡啶环上发生。提出了氧化还原机制并讨论了其对蛋白酶体抑制的影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d48b/7526604/b2f7f7298900/sc2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d48b/7526604/1ba2266e798b/ga1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d48b/7526604/f299d84e1651/sc1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d48b/7526604/4cc849b8782d/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d48b/7526604/b2e6e0df5ecb/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d48b/7526604/d572bb7cf802/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d48b/7526604/418d255df2db/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d48b/7526604/3c8b79080574/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d48b/7526604/c81df4fde6f1/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d48b/7526604/77b253175420/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d48b/7526604/8ef05662a2a5/gr8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d48b/7526604/b2f7f7298900/sc2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d48b/7526604/1ba2266e798b/ga1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d48b/7526604/f299d84e1651/sc1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d48b/7526604/4cc849b8782d/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d48b/7526604/b2e6e0df5ecb/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d48b/7526604/d572bb7cf802/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d48b/7526604/418d255df2db/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d48b/7526604/3c8b79080574/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d48b/7526604/c81df4fde6f1/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d48b/7526604/77b253175420/gr7_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d48b/7526604/8ef05662a2a5/gr8_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d48b/7526604/b2f7f7298900/sc2_lrg.jpg

相似文献

1
Charge transfer reaction mechanisms of epoxyketone and boronated peptides at glassy carbon and boron doped diamond electrodes.环氧酮与硼化肽在玻碳电极和硼掺杂金刚石电极上的电荷转移反应机理
J Electroanal Chem (Lausanne). 2020 Dec 1;878:114733. doi: 10.1016/j.jelechem.2020.114733. Epub 2020 Sep 30.
2
Electrochemical evaluation and determination of antiretroviral drug fosamprenavir using boron-doped diamond and glassy carbon electrodes.电化学评价和测定抗逆转录病毒药物福沙那韦使用掺硼金刚石和玻碳电极。
Anal Bioanal Chem. 2010 May;397(1):189-203. doi: 10.1007/s00216-009-3334-3. Epub 2009 Dec 10.
3
Boron doped diamond and glassy carbon electrodes comparative study of the oxidation behaviour of cysteine and methionine.硼掺杂金刚石和玻璃碳电极对半胱氨酸和蛋氨酸氧化行为的比较研究。
Bioelectrochemistry. 2011 Apr;81(1):46-52. doi: 10.1016/j.bioelechem.2011.02.001. Epub 2011 Feb 24.
4
Electroanalytical investigation and determination of pefloxacin in pharmaceuticals and serum at boron-doped diamond and glassy carbon electrodes.硼掺杂金刚石电极和玻碳电极用于药物及血清中培氟沙星的电分析研究与测定
Talanta. 2008 Feb 15;74(5):1191-200. doi: 10.1016/j.talanta.2007.08.023. Epub 2007 Aug 30.
5
Boron-doped diamond electrodes for the electrochemical oxidation and cleavage of peptides.硼掺杂金刚石电极用于肽的电化学氧化和断裂。
Anal Chem. 2013 Jul 16;85(14):6626-32. doi: 10.1021/ac303795c. Epub 2013 Jun 25.
6
Calcium channel blocker lercanidipine electrochemistry using a carbon black-modified glassy carbon electrode.使用碳黑修饰玻碳电极的钙通道阻滞剂乐卡地平电化学。
Anal Bioanal Chem. 2020 Sep;412(24):6381-6389. doi: 10.1007/s00216-020-02591-y. Epub 2020 Apr 8.
7
Myocyte-Damaging Effects and Binding Kinetics of Boronic Acid and Epoxyketone Proteasomal-Targeted Drugs.硼酸和环氧酮蛋白酶体靶向药物的心肌细胞损伤作用及结合动力学。
Cardiovasc Toxicol. 2018 Dec;18(6):557-568. doi: 10.1007/s12012-018-9468-9.
8
Investigation of electrochemical behavior of lipid lowering agent atorvastatin calcium in aqueous media and its determination from pharmaceutical dosage forms and biological fluids using boron-doped diamond and glassy carbon electrodes.降脂药物阿托伐他汀钙在水性介质中的电化学行为研究及其在药物剂型和生物流体中的硼掺杂金刚石和玻碳电极测定
Comb Chem High Throughput Screen. 2007 Aug;10(7):571-82. doi: 10.2174/138620707782152407.
9
Electrochemical behavior of triflusal, aspirin and their metabolites at glassy carbon and boron doped diamond electrodes.曲氟尿苷、阿司匹林及其代谢物在玻碳电极和硼掺杂金刚石电极上的电化学行为。
Comb Chem High Throughput Screen. 2010 Aug;13(7):569-77. doi: 10.2174/1386207311004070569.
10
Electrochemical oxidation of histamine and serotonin at highly boron-doped diamond electrodes.组胺和血清素在高硼掺杂金刚石电极上的电化学氧化
Anal Chem. 2000 Apr 1;72(7):1632-8. doi: 10.1021/ac9908748.

本文引用的文献

1
A historical perspective on milestones in multiple myeloma research.多发性骨髓瘤研究里程碑的历史回顾。
Eur J Haematol. 2018 Mar;100(3):221-228. doi: 10.1111/ejh.13003. Epub 2017 Dec 27.
2
A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results.一项评估马立佐米、泊马度胺和低剂量地塞米松用于复发和难治性多发性骨髓瘤的1期临床试验(NPI-0052-107):最终研究结果
Br J Haematol. 2018 Jan;180(1):41-51. doi: 10.1111/bjh.14987. Epub 2017 Oct 26.
3
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial.
卡非佐米或硼替佐米治疗复发或难治性多发性骨髓瘤(ENDEAVOR):一项开放标签、随机、3 期临床试验的中期总生存分析。
Lancet Oncol. 2017 Oct;18(10):1327-1337. doi: 10.1016/S1470-2045(17)30578-8. Epub 2017 Aug 23.
4
The activity and safety of novel proteasome inhibitors strategies (single, doublet and triplet) for relapsed/refractory multiple myeloma.新型蛋白酶体抑制剂策略(单药、双药和三药)治疗复发/难治性多发性骨髓瘤的活性和安全性。
Acta Oncol. 2018 Feb;57(2):290-296. doi: 10.1080/0284186X.2017.1364868. Epub 2017 Aug 22.
5
Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting.多发性骨髓瘤治疗的神奇之年:2015年美国血液学会年会的关键要点
Oncotarget. 2017 Feb 7;8(6):10748-10759. doi: 10.18632/oncotarget.13314.
6
Proteasome inhibitors.蛋白酶体抑制剂。
Biochem Pharmacol. 2015 Jul 1;96(1):1-9. doi: 10.1016/j.bcp.2015.04.008. Epub 2015 Apr 29.
7
Crystal structure of the human 20S proteasome in complex with carfilzomib.人20S蛋白酶体与卡非佐米复合物的晶体结构
Structure. 2015 Feb 3;23(2):418-24. doi: 10.1016/j.str.2014.11.017. Epub 2015 Jan 15.
8
Bortezomib for the treatment of multiple myeloma.硼替佐米用于治疗多发性骨髓瘤。
Expert Rev Hematol. 2014 Apr;7(2):173-85. doi: 10.1586/17474086.2014.899144.
9
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.一项单药卡非佐米(PX-171-003-A1)治疗复发/难治性多发性骨髓瘤患者的 II 期研究。
Blood. 2012 Oct 4;120(14):2817-25. doi: 10.1182/blood-2012-05-425934. Epub 2012 Jul 25.
10
Proteasome inhibitors in multiple myeloma: 10 years later.蛋白酶体抑制剂在多发性骨髓瘤中的应用:10 年进展。
Blood. 2012 Aug 2;120(5):947-59. doi: 10.1182/blood-2012-04-403733. Epub 2012 May 29.